The combined down-regulation of RELA and MMP9 expression upon SHN3 silencing inhibits tumor growth and cancer invasion, supporting a potential therapeutic value for SHN3 targeting in IL13Rα2-positive tumors. Here, IL13RA2 is linked to neoplasm.